Welcome to our dedicated page for AVAI BIO news (Ticker: AVAI), a resource for investors and traders seeking the latest updates and insights on AVAI BIO stock.
Avant Technologies Inc. (OTCQB: AVAI) issues frequent updates about its joint ventures, licensing agreements, and development programs in biotechnology and healthcare-focused artificial intelligence. Its news releases describe how the company is building a partnership-driven model around genetically modified cell lines, encapsulation technologies, and AI platforms that target chronic and age-related diseases.
Recent news has highlighted Avant’s joint venture with SGAustria Pte. Ltd. to form Insulinova, Inc., which is intended to develop cell-based therapies for type 1 and some insulin-dependent type 2 diabetes using insulin-producing cells combined with encapsulation technology. Other announcements cover the creation and progress of Klothonova, a 50/50 joint venture with Austrianova that is developing encapsulated Klotho-producing cell therapies for age-related conditions, including cardiovascular and neurodegenerative diseases.
Avant also reports on its collaboration with Ainnova Tech, Inc. through a joint venture that holds worldwide licensing rights to Ainnova’s Vision AI platform for early detection of diabetic retinopathy. News items describe regulatory interactions with the U.S. Food and Drug Administration, refinements to clinical trial protocols, and plans for patient recruitment in multiethnic populations at community and primary care sites.
Investors and observers following AVAI news can expect coverage of new joint venture agreements, updates on cell-based therapy programs, progress toward preclinical and clinical milestones, and developments in AI-based diagnostic initiatives. The company’s press releases also document corporate actions such as a proposed name change to Avaí Bio, Inc. and clarifications like the retraction of a previously announced but non-binding joint venture. This news feed allows readers to track how Avant’s partnership strategy evolves across its diabetes, longevity, and AI-driven healthcare efforts.
Avant Technologies (OTCQB: AVAI) and its partner Ainnova Tech announced that Ainnova will sponsor and present at the 2025 Healthcare Innovation Summit in Mexico City. Ainnova's CEO Vinicio Vargas will deliver a presentation titled 'Preventative Healthcare with Artificial Intelligence: Breaking the Status Quo.'
The companies have formed Ai-nova Acquisition Corp. (AAC), which holds global licensing rights for Ainnova's technology portfolio, including its Vision AI platform and retinal cameras. The Healthcare Innovation Summit Series is a global event bringing together key stakeholders such as government officials, regulators, hospital administrators, and clinical experts to discuss healthcare transformation, systems optimization, and digital innovation.
Avant Technologies (OTCQB: AVAI) and its partner Ainnova Tech have initiated the design of clinical trial protocols for their Vision AI platform, focusing on early detection of diabetic retinopathy. The companies are preparing for a pre-submission meeting with the FDA scheduled for mid-May 2025, which will guide the clinical testing requirements for their 510(k) clearance application.
An ophthalmologist has been hired to assist in drafting the trial protocol requirements requested by their Contract Research Organization (CRO), Fortrea. The technology is being developed through Ai-nova Acquisition Corp. (AAC), a joint venture holding global licensing rights to Ainnova's technology portfolio, including the Vision AI platform and retinal cameras.
The FDA pre-submission program will help determine the regulatory pathway, including patient and clinic requirements for clinical data generation, and enable Avant to establish a precise budget for the FDA process.
Avant Technologies (OTCQB:AVAI) and its partner Ainnova Tech have announced a strategic collaboration with Apollo Hospitals to advance AI in healthcare. Ainnova has secured exclusive licenses for AI algorithms validated with over 2.3 million data points for their Vision AI platform.
The platform enables early detection of various conditions including cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, and lung abnormalities. Following Avant and Ainnova's recent global development deal through their joint venture AAC, the AI diagnostics will be launched commercially across the Americas in the coming weeks.
The partnership has already received regulatory approval from ANVISA for expansion into Brazil's 200-million-person market. The collaboration aims to enhance chronic disease management by facilitating early referrals from primary care providers and community health services to specialists.
Avant Technologies Inc. (OTCQB:AVAI) and its partner Ainnova Tech have expanded their joint venture agreement to include a global license for developing and marketing Ainnova's technology portfolio. The partnership, through Ai-nova Acquisition Corp. (AAC), will focus on advancing Ainnova's Vision AI platform and proprietary retinal camera technology.
The Vision AI platform can detect diabetic retinopathy and other retinal diseases, as well as non-retinal conditions like cardiovascular disease, prediabetes, type 2 diabetes, fatty liver diseases, and chronic kidney disease using retinal scans. Under the amended agreement, AAC will have global SaaS and hardware commercialization opportunities with opticians and eye care centers.
This expansion comes ahead of Ainnova's meetings with the FDA to prepare for a planned clinical trial of its Vision AI platform. Ainnova will request a pre-submission meeting for guidance on clinical testing for diabetic retinopathy detection, leading to an FDA 510(k) submission. For Avant, these FDA interactions will help define the budget for the regulatory process and are important for marketing the technology in the United States.
Avant Technologies (OTCQB:AVAI) announced that Vinicio Vargas, CEO of their joint venture partner Ainnova Tech and board member of Ai-nova Acquisition Corp (AAC), will be a featured speaker at the 2025 AI Revolution in Healthcare Summit in Dubai on February 15-16.
Vargas will address experts and investors about the clinical adoption of AI in healthcare, focusing on how it improves diagnostics and expands access to underserved communities. His presentation will cover key adoption drivers like investments in telemedicine and AI-powered imaging, while discussing challenges in data standardization, regulatory compliance, and workforce training.
As a panelist, he will participate in discussions about ethics in healthcare AI deployment, including data privacy, algorithmic bias, transparency in AI decision-making, and regulatory compliance across regions.
Avant Technologies (OTCQB:AVAI) and its partner Ainnova Tech have selected Fortrea as their Contract Research Organization (CRO) for upcoming FDA clinical trials. The trials will focus on seeking FDA approval for Ainnova's Vision AI platform, specifically for early detection of diabetic retinopathy.
Fortrea will assist in requesting a pre-submission FDA meeting expected in late March/early April 2025, followed by clinical studies and an FDA 510(k) submission. Through their joint venture, Ai-nova Acquisition Corp. (AAC), the companies hold licensing rights for the technology portfolio in the U.S., Canada, and Europe.
Additionally, Ainnova plans to seek FDA clearance for four recently acquired algorithms targeting early detection of cardiovascular risk, prediabetes and Type 2 diabetes, fatty liver disease, and chronic kidney disease.
Avant Technologies (OTCQB: AVAI) and its partner Ainnova Tech have secured exclusive licenses for four AI-driven healthcare algorithms from a major Asian healthcare institution. These algorithms, validated with over 2 million patient data points, focus on early detection of cardiovascular risk, prediabetes, Type 2 diabetes, fatty liver disease, and chronic kidney disease. The solutions will be integrated into Ainnova's VisionAI platform, with plans to launch in Latin American markets and pursue FDA clearance in 2025 for US market entry.
The broader AI market reached $184 billion in 2024, showing a $50 billion increase from 2023, with projections to exceed $826 billion by 2030. Healthcare remains a critical application area for AI, focusing on improving diagnostics, personalizing treatment plans, and optimizing patient care.
Avant Technologies (OTCQB: AVAI) and partner Ainnova Tech have secured exclusive licensing for 4 AI-driven disease detection algorithms from a major Asian healthcare institution. The algorithms, validated across 2+ million patients, target early detection of cardiovascular risk, prediabetes/Type 2 diabetes, fatty liver disease, and chronic kidney disease.
These solutions will integrate with Ainnova's VisionAI platform and existing retinal disease detection tools. The partnership plans to launch in Latin American markets and aims for FDA clearance in 2025 for U.S. market entry. The algorithms show impressive performance metrics, including 90%+ precision in coronary artery disease risk prediction and 88%+ accuracy in liver fibrosis screening.
Avant Technologies (OTCQB: AVAI) partner, Ainnova Tech, has announced a strategic alliance with Roche and Salud 360 to launch a pilot program combating diabetic retinopathy in Costa Rica. The program will utilize Ainnova's AI technology and non-mydriatic fundus cameras to analyze retinal images for early detection of the disease.
The initiative targets Costa Rica, where diabetes affects 10.4% of adults, with 20-40% of diabetic patients developing diabetic retinopathy. The program aims to prevent blindness through early detection, as 80% of diabetes-related blindness cases are preventable with timely intervention. If successful, Avant and Ainnova plan to expand the program to the United States, Canada, and Europe through their joint venture, Ai-nova Acquisition Corp (AAC).
Avant Technologies (OTCQB: AVAI) and Ainnova Tech announced plans to advance a proprietary low-cost retinal camera integrated with Ainnova's Vision AI software platform. The combined technology will provide retinal scans for early disease detection, including diabetic retinopathy, glaucoma, macular edema, and other conditions. The system will be marketed as a Software as a Service (SaaS) + retinal camera package through Ai-nova Acquisition Corp (AAC), targeting primary care clinics, insurance companies, opticians, and pharmacies with a pay-per-use model. AAC holds licensing rights for North America and Europe.